Cochlear Implant Bilateral denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cochlear implant bilateral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Bilateral Cochlear Implants as Experimental

Blue Cross Blue Shield may classify simultaneous or sequential bilateral cochlear implantation as experimental or investigational — meaning its internal medical policy has not recognized bilateral implantation as established standard of care, even though unilateral implantation may be covered. This most commonly affects the second implant when BCBS's policy was written or last updated before bilateral implantation achieved broad specialty-society acceptance, or when the plan draws a distinction between adult and pediatric bilateral implantation.

## Why This Denial Is Appealable

Bilateral cochlear implantation is recognized as clinically beneficial by major professional societies in otolaryngology and audiology. Coverage policies that continue to classify bilateral implantation as experimental often reflect a publication lag rather than current clinical consensus. If the treating team can demonstrate that bilateral implantation is consistent with current specialty guidelines and that this patient's clinical circumstances meet the criteria recognized in those guidelines, the experimental label is challengeable. External reviewers — independent of BCBS — frequently reverse experimental denials when specialty society support is well documented.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plans) or applicable state law within the deadline on the denial notice — typically 180 days.
• External review: ACA §2719 provides independent external review after internal exhaustion. The standard window is approximately four months from the final internal denial; confirm on your notice.
• Expedited review: For pediatric patients or others for whom delay causes developmental or safety risk, request expedited external review — decisions typically within 72 hours.

## Concrete Appeal Steps

1. Obtain BCBS's medical policy for cochlear implants and note the evidence-review date. If the policy is more than two to three years old, that gap is itself an argument. 2. Identify the specific professional society guidelines (e.g., American Academy of Otolaryngology–Head and Neck Surgery, American Academy of Audiology) that recognize bilateral implantation as clinically appropriate for the patient's presentation. 3. Have the implanting surgeon write a letter directly addressing BCBS's experimental criteria — typically a policy will list elements such as published peer-reviewed evidence, specialist consensus, and FDA clearance status. Address each element. 4. Confirm the FDA clearance status of the implant system being used for the second ear — most cochlear implant systems cleared for one ear are cleared for bilateral use.

## Documentation to Gather

• Diagnosis and audiologic records confirming the severity of hearing loss in both ears
• Implanting surgeon's letter documenting clinical rationale for bilateral implantation and consistency with current specialty standards
• Audiologist's functional assessment explaining the limitations of unilateral implantation for this patient
• Professional society guideline documents (by organization name and publication title) supporting bilateral implantation
• FDA clearance documentation for the implant device, including any bilateral-use indication
• For pediatric patients: developmental records, speech-language pathology assessment, and documentation of the time-sensitive nature of implantation during critical developmental windows

## Criteria-Mapping Structure

Obtain the BCBS medical policy for cochlear implants, including the section defining experimental criteria. List each element of the experimental designation. For each element — such as whether the procedure has achieved specialist consensus, whether it has been cleared by the FDA, and whether it is generally accepted as standard practice — provide a direct, documented response from the treating team's records and the applicable professional society guidance.